France European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both the US and China every year; recent data from ING shows that the percentage of global new drug approvals originating…
France Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path for others to follow. Amolyt Pharma When AstraZeneca’s rare diseases arm Alexion acquired Lyon-based Amolyt Pharma in a deal…
France In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state subsidies in rival markets. “France’s industrial fabric risks being systematically hollowed out if we don’t act fast to mitigate…
France MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and early scientific partnerships shaped a platform now approaching its first potential approval for its first microbiome drug candidate. The journey…
France The biggest stories from French healthcare and pharma, including AstraZeneca’s acquisition of Amolyt Pharma; protests over Sanofi layoffs; Pierre Fabre’s purchase of Kinnate Biopharma’s experimental pan-RAF inhibitor, and French biotech SeaBeLife’s EUR 1.5 million funding round. Withdrawal of a flu vaccine due to a price dispute between Sanofi and…
France The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs to Pharmanovia and Servier’s EUR 120 million investment in its largest global site located in France. Hospital crisis: at…
See our Cookie Privacy Policy Here